...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Network Pharmacology-Based Strategy for Predicting Therapy Targets of Traditional Chinese Medicine Xihuang Pill on Liver Cancer
【24h】

Network Pharmacology-Based Strategy for Predicting Therapy Targets of Traditional Chinese Medicine Xihuang Pill on Liver Cancer

机译：基于网络药理学的基于肝癌的中医治疗目标的策略

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. To investigate the potential therapy targets and pharmacological mechanism of traditional Chinese medicine (TCM) Xihuang pill in liver cancer based on network pharmacology. Methods. Drug ingredients-target network was constructed based on the target sets of Xihuang pill and liver cancer. The overlapping genes between Xihuang pill targets and liver cancer-related molecular targets were investigated using comparative analysis. Moreover, the PPI network and module was constructed based on overlapping genes and hub nodes, respectively, followed by the pathway enrichment analysis. Results. A drug ingredients-target network was established with 1184 nodes and 11035 interactions. Moreover, a total of 106 overlapping genes were revealed between drug targets and liver cancer molecular targets. Furthermore, a PPI network and 4 modules were further investigated based on overlapping genes, respectively. These hub nodes such as VEGFA and EGFR were mainly enriched in GO functions including positive regulation of MAP kinase activity, activation of protein kinase activity, regulation of MAP kinase activity, and pathways like proteoglycans in cancer, bladder cancer, and estrogen signaling. Conclusion. VEGFA and EGFR might be potential therapy targets of Xihuang pill in liver cancer. Furthermore, the effect of Xihuang pill on liver cancer might be realized by targeting VEGFA and EGFR in pathways like proteoglycans in cancer and estrogen signaling.
机译：客观的。基于网络药理学的肝癌中药（TCM）Xihuang丸的潜在治疗靶点和药理机制。方法。基于Xihuang丸和肝癌的目标套，构建了药物成分 - 目标网络。使用比较分析研究了Xihuang丸靶和肝癌相关​​分子靶标的重叠基因。此外，PPI网络和模块分别基于重叠基因和集线器节点构建，然后是途径富集分析。结果。用1184个节点和11035个相互作用建立了药物成分 - 目标网络。此外，在药物靶标和肝癌分子靶标之间揭示了总共106个重叠基因。此外，基于重叠基因进一步研究了PPI网络和4个模块。这些具有VEGFA和EGFR的集线器节点主要富集，包括对MAP激酶活性的阳性调节，蛋白激酶活性的激活，MAP激酶活性的激活，以及癌症，膀胱癌和雌激素信号中的蛋白多糖等途径。结论。 VEGFA和EGFR可能是肝癌中Xihuang丸的潜在治疗目标。此外，通过在癌症和雌激素信号传导中诱导蛋白多糖等途径靶向VEGFA和EGFR，可以实现Xihuang丸对肝癌的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号